32.jpg)
56.jpg)
NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL
Patent number:
US2022119816
No items found.
Provided herein are methods, compounds, and compositions for reducing expression of MAT1a in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual.
Countries:
Spain
Regions:
Basque Country
Centers:
EUSKAL HERRIKO UNBERTSITATEA
Other entities:
Sectors:
Health
Subsectors:
Pharmaceuticals, Biotechnology, C12Y205/01006
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
BRL2: First business concept described market potential & competitive overview
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
Methods, compounds, and compositions useful for reducing expression or activity of methionine adenosyltransferase 1a in an individual. Also, MAT1a specific inhibitors, which can be useful in reducing MAT1a related diseases or conditions in an individual. Such methods, compounds, and compositions can be useful, for example to treat. prevent, delay or ameliorate metabolic disease in an individual.
Comments
Other related patents
Health
COMBINATIONS WITH THIAZOLIDINEDIONES FOR USE IN THE PREVENTION OR TREATMENT OF ABNORMAL BONE GROWTH
Health
BIOMARKERS FOR DIAGNOSIS, PROGNOSIS, PREVENTION, IMPROVEMENT OR RELIEF IN THE TREATMENT OF CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Health